 |
|
SU011248 versus Interferon-alfa as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma
Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
A6181034
NCT00083889
|
|
|
Trial Description
Summary The purpose of this study is to test whether SU011248 has activity and is safe compared to Interferon-alfa in patients with metastatic Renal Cell Carcinoma (RCC). Eligibility Criteria Inclusion Criteria: - Histologically confirmed renal cell carcinoma of clear cell histology with metastases
- Evidence of measurable disease by radiographic technique
- Male or female, 18 years or older
- ECOG performance status of 0 or 1
- Resolution of all acute toxicities of prior therapies
- Adequate organ function
Exclusion Criteria: - Prior systemic (including adjuvant or neoadjuvant) therapy of any kind for RCC
- Major surgery or radiation therapy within 4 weeks
- Severe hemorrhage within 4 weeks
- Diagnosis of a second malignancy within the last 5 years
- History of or known brain metastases, spinal cord compression or carcinomatous meningitis
- Serious acute or chronic illness or recent history of significant cardiac abnormality
- Pre-existing thyroid abnormality with thyroid function that cannot be controlled by medication
- Known HIV or AIDS-related illness
- Current treatment on another clinical trial
Trial Contact Information
Trial Lead Organizations/Sponsors Pfizer Incorporated | SU011248 Clinical Trial Information Service: | | Ph: 877-416-6248 |
| [NEW LOCATIONS ARE UPDATED TO THIS WEBSITE MONTHLY...... FOR MORE CURRENT INFORMATION, PLEASE CALL THE NUMBER LISTED.] | | |
Trial Sites
|
|
|
|
| U.S.A. |
|
| California |
|
| |
San Francisco |
|
| | | | | | | | | Pfizer Investigational Site |
|
| Louisiana |
|
| |
Chalmette |
|
| | | | Pfizer Investigational Site |
|
| |
Covington |
|
| | | Pfizer Investigational Site |
|
| |
Metairie |
|
| | | Pfizer Investigational Site |
|
| |
New Orleans |
|
| | | Pfizer Investigational Site |
|
| Nebraska |
|
| |
Omaha |
|
| | | | Pfizer Investigational Site |
|
| New Hampshire |
|
| |
Lebanon |
|
| | | | Pfizer Investigational Site |
|
| New Mexico |
|
| |
Farmington |
|
| | | | Pfizer Investigational Site |
|
| New York |
|
| |
New York |
|
| | | | Pfizer Investigational Site |
|
| Ohio |
|
| |
Cleveland |
|
| | | | Pfizer Investigational Site |
|
| Oregon |
|
| |
Portland |
|
| | | | Pfizer Investigational Site |
|
| Texas |
|
| |
Dallas |
|
| | | | Pfizer Investigational Site |
|
| Wisconsin |
|
| |
Madison |
|
| | | | Pfizer Investigational Site |
|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00083889
Information obtained from ClinicalTrials.gov on 2004-11-09 Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top |
|
